Product logins

Find logins to all Clarivate products below.


Due to rising antibiotic resistance rates, powerful antibiotics historically reserved for later lines of therapy are becoming standard-of-care treatment for gram-negative infections (GNIs), particularly those acquired in healthcare facilities (e.g. hospitals, nursing homes, and long-term care facilities). Rising antimicrobial resistance rates have created an urgent need for new therapies with activity against multidrug-resistant gram-negative pathogens. As a result, commercial opportunities remain, particularly in the hospital setting, for emerging brands demonstrating clinical efficacy in patients with resistant infections, and especially those associated with high rates of mortality. Our Current Treatment content provides deep insights drawn from a survey of 100 hospital-based infectious diseases specialists, regarding how GNI inpatients are being treated in the United States today, and what factors are behind those treatment decisions.

Related Market Assessment Reports

Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…
Report
Atopic Dermatitis / Atopic Eczema – Access & Reimbursement – Access & Reimbursement – Atopic Dermatitis (US)
The treatment landscape for AD in the United States is evolving rapidly. Since 2017, the FDA has approved multiple agents, including systemic and topical JAK inhibitors, nonsteroidal topical…
Report
Renal Anemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Renal Anemia (US)
Renal anemia is a common complication of chronic kidney disease (CKD). When kidneys are diseased or impaired, they fail to generate enough EPO, causing renal anemia. The primary goal of renal…
Report
Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)
Painful diabetic neuropathy (PDN) is characterized by numbness, tingling, and burning, sharp, shooting, or other painful sensations, commonly in the feet, legs, and/or hands. PDN is managed with…
Report
Biosimilars – Current Treatment – Endocrinology
Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine to launch in Europe and the United States, followed by Sanofi’s Admelog / Insulin…